Introduction
============

Annual cancer incidence and mortality continue to rise worldwide. There were \~12.7 million new cases and 7.6 million new deaths in 2008.[@b1-ott-9-1381] Although the pathogenetic mechanism of cancer has not been fully understood, extensive evidence has indicated the important roles of polymorphisms in the key genes during the process of carcinogenesis.[@b2-ott-9-1381]--[@b4-ott-9-1381] Screening and identification of single nucleotide polymorphisms that are related to cancer susceptibility would greatly benefit individuals at high risk of cancer in the early prevention and treatment settings.

Caveolin-1 (CAV1) is a member of the caveolin family of proteins and has been proved to modulate multiple cancer-associated processes, including cellular transformation, tumor growth, cell migration and metastasis, cell death and survival, and angiogenesis in a number of signaling pathways.[@b5-ott-9-1381]--[@b7-ott-9-1381] Thus, CAV1 is thought to play an important role in tumor development and progression. The *CAV1* gene is located on the human chromosome 7q31.1 and has some potentially functional polymorphisms identified. Among these polymorphisms, the associations of *CAV1* G14713A polymorphism and cancer susceptibility have been widely investigated; however, results are conflicting.[@b8-ott-9-1381]--[@b19-ott-9-1381] For instance, Liu et al reported significant positive associations between *CAV1* G14713A polymorphism and the risk of breast cancer.[@b16-ott-9-1381] However, Wu et al reported no significant association between *CAV1* G14713A polymorphism and risk of prostate cancer.[@b14-ott-9-1381] Based on these observations, we conducted the present meta-analysis to clarify the role of *CAV1* G14713A polymorphism in carcinogenesis.

Methods
=======

Publication search and inclusion criteria
-----------------------------------------

We searched electronic databases containing PubMed, Chinese National Knowledge Infrastructure, and Chinese Biology Medicine up to June 2015, using the following terms: "caveolin-1 or CAV1" AND "genetic polymorphism or polymorphisms or variant" AND "cancer or carcinoma or tumor". Additional studies were identified by hand-searching references of original or review articles on this topic. If data were published in more than one article, only the publication with the largest sample size was included. Studies were selected according to the following criteria: 1) studies should have evaluated the association between *CAV1* G14713A polymorphism and cancer susceptibility; 2) the type of study design should be a case-control study; and 3) studies should have a detailed genotype frequency of cases and controls.

Data extraction
---------------

Two investigators independently screened the studies and extracted the following data from the included studies: first author's name, publication year, ethnicity, cancer type, total number of cases and controls, and genotype distributions in cases and controls. Disagreements were resolved through discussion with another investigator.

Statistical analysis
--------------------

Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated to assess the strength of associations of *CAV1* G14713A polymorphism with cancer susceptibility. ORs were calculated using five genetic models: homozygous (AA vs GG), heterozygous (AG vs GG), dominant (\[AA + AG\] vs GG), recessive (AA vs \[AG + GG\]), and allele contrast (A vs G). Subgroup analysis was also conducted according to the type of cancer. Heterogeneity among studies was assessed using the *Q*-test and *I*^2^ statistics. When heterogeneity was considered significant (*P*~het~\<0.05 or *I*^2^\>50%), a random-effect model was used; otherwise, a fixed-effect model was used. Sensitivity analysis was performed by removing the single studies, one at a time and recalculating the summarized ORs. Potential publication bias of the included studies was assessed by Begg's funnel plots and Egger's test. All *P*-values were two sided, and all analyses were carried out with STATA 12.0 software package (Stata Corporation, College Station, TX, USA).

Results
=======

Characteristics of studies and main results
-------------------------------------------

As shown in [Figure 1](#f1-ott-9-1381){ref-type="fig"}, we initially extracted 56 articles in relation to the search words. Among them, 12 articles that met the inclusion criteria were included in this study. The principle characteristics of the 12 eligible studies are summarized in [Tables 1](#t1-ott-9-1381){ref-type="table"} and [2](#t2-ott-9-1381){ref-type="table"}. Six studies were conducted on digestive system cancer and six studies on cancer of other systems. The main meta-analysis results and the heterogeneities are shown in [Table 3](#t3-ott-9-1381){ref-type="table"} and [Figure 2](#f2-ott-9-1381){ref-type="fig"}. In the overall analysis, *CAV1* G14713A polymorphism showed a significant association with increased risk of cancer (A vs G: OR =1.77, 95% CI: 1.49--2.10, *P*~het~\<0.01; \[AA + AG\] vs GG: OR =2.03, 95% CI: 1.64--2.53, *P*~het~\<0.01; AA vs \[AG + GG\]: OR =1.72, 95% CI: 1.40--2.12, *P*~het~\<0.01; AA vs GG: OR =2.24, 95% CI: 1.69--2.98, *P*~het~\<0.01; AG vs GG: OR =1.98, 95% CI: 1.62--2.41, *P*~het~\<0.01). In addition, the results of stratified analysis by tumor type suggested that *CAV1* G14713A polymorphism was associated with an increased risk of digestive system cancer (A vs G: OR =2.02, 95% CI: 1.75--2.33, *P*~het~=0.03; \[AA + AG\] vs GG: OR =2.40, 95% CI: 1.94--2.98, *P*~het~\<0.01; AA vs \[AG + GG\]: OR =2.01, 95% CI: 1.68--2.40, *P*~het~=0.83; AA vs GG: OR =2.84, 95% CI: 2.36--3.42, *P*~het~=0.32; AG vs GG: OR =2.30, 95% CI: 1.84--2.88, *P*~het~=0.01) and cancer of other systems (A vs G: OR =1.55, 95% CI: 1.18--2.03, *P*~het~\<0.01; \[AA + AG\] vs GG: OR =1.72, 95% CI: 1.25--2.36, *P*~het~\<0.01; AA vs \[AG + GG\]: OR =1.49, 95% CI: 1.06--2.10, *P*~het~=0.01; AA vs GG: OR =1.81, 95% CI: 1.16--2.84, *P*~het~\<0.01; AG vs GG: OR =1.69, 95% CI: 1.28--2.24, *P*~het~\<0.01).

Sensitivity analysis and publication bias
-----------------------------------------

A sensitivity analysis was performed by omitting every study in turn to check the influence of the removed data. Pooled estimates for all genetic models were insensitive to the removal of individual study, and the corresponding pooled ORs were not substantially altered, suggesting that our results were stable and reliable ([Figure 3](#f3-ott-9-1381){ref-type="fig"}). Both Begg's funnel plots and Egger's test were performed to examine the underlying publication bias ([Figure 4](#f4-ott-9-1381){ref-type="fig"}). The symmetrical funnel plots and *P*-value \>0.05 for Egger's test indicated no publication bias in this meta-analysis.

Discussion
==========

CAV1 is the major structural protein in caveolae and consists of 178 amino acids; it has been identified as a tumor suppressor in 1989.[@b20-ott-9-1381] CAV1 plays an important role in many signaling pathways, molecular transport, and cellular proliferation and differentiation, which are potentially involved in the development of human cancer.[@b21-ott-9-1381] The association of *CAV1* G14713A polymorphism with cancer risk has been widely reported, but results are conflicting. For example, some studies indicated that *CAV1* G14713A polymorphism was associated with cancer risk, such as esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, and breast cancer.[@b9-ott-9-1381],[@b10-ott-9-1381],[@b12-ott-9-1381],[@b16-ott-9-1381] Other studies demonstrated that *CAV1* G14713A polymorphism was not associated with the risk of cancer, including prostate cancer and nasopharyngeal carcinoma.[@b14-ott-9-1381],[@b15-ott-9-1381] To provide a more detailed overview of the association, five genetic models were used in the current meta-analysis. To our knowledge, this is the first meta-analysis of the association between *CAV1* G14713A polymorphism and cancer risk, and the results suggested that *CAV1* G14713A polymorphism increased the risk of cancer. In the subgroup analysis by tumor type, *CAV1* G14713A polymorphism was significantly associated with an increased risk of digestive system cancer and cancer of other systems.

Our meta-analysis had some advantages. For instance, we strictly obeyed the inclusion and exclusion criteria to reduce selection bias. Furthermore, there was no evidence of publication bias in this meta-analysis, and the sensitivity analysis confirmed the reliability and stability of the results. Despite these advantages, limitations should be considered when interpreting our results. First, our results were based on unadjusted estimates. More analyses that are precise can be conducted if individual data, including age and sex, were available. Second, all published studies were based on Asian populations. Therefore, the results of this meta-analysis may be applicable to the specified ethnicity alone.

Conclusion
==========

The present study demonstrated that *CAV1* G14713A polymorphism might contribute to individual susceptibility to cancer. However, further well-designed studies are required to evaluate this association.
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![Forest plots representing the pooled results of ORs for the association between *CAV1* G14713A polymorphism and overall cancer risk.\
**Note:** Weights are from random effects analysis.\
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![Begg's funnel plots of the association between *CAV1* G14713A polymorphism and overall cancer risk.\
**Abbreviations:** SE, standard error of the logOR; logOR, natural logarithm of the OR; OR, odds ratio; *CAV1*, *caveolin-1*.](ott-9-1381Fig4){#f4-ott-9-1381}

###### 

Main characteristics of included studies

  First author                   Ethnicity   Cancer type                                                    Case    Control
  ------------------------------ ----------- -------------------------------------------------------------- ------- ---------
  Wang et al[@b8-ott-9-1381]     Asian       Esophageal squamous cell carcinoma (digestive system cancer)   427     427
  Zhang et al[@b9-ott-9-1381]    Asian       Gastric cancer (digestive system cancer)                       412     412
  Lin et al[@b10-ott-9-1381]     Asian       Gastric cancer (digestive system cancer)                       358     358
  Wang et al[@b11-ott-9-1381]    Asian       Leukemia (other system cancer)                                 266     266
  Hsu et al[@b12-ott-9-1381]     Asian       Hepatocellular carcinoma (digestive system cancer)             298     298
  Chang et al[@b13-ott-9-1381]   Asian       Upper urothelial tract cancer (other system cancer)            218     580
  Wu et al[@b14-ott-9-1381]      Asian       Prostate cancer (other system cancer)                          250     500
  Tsou et al[@b15-ott-9-1381]    Asian       Nasopharyngeal carcinoma (other system cancer)                 176     176
  Liu et al[@b16-ott-9-1381]     Asian       Breast cancer (other system cancer)                            1,232   1,232
  Bau et al[@b17-ott-9-1381]     Asian       Oral cancer (digestive system cancer)                          620     620
  Bau et al[@b18-ott-9-1381]     Asian       Bladder cancer (other system cancer)                           375     375
  Yang et al[@b19-ott-9-1381]    Asian       Colorectal cancer (digestive system cancer)                    362     362

###### 

Allele frequency and genotype distributions of cases and controls in included studies

  First author                   Case (G14713A)   Control (G14713A)                                                                             
  ------------------------------ ---------------- ------------------- ----- ----- ------- ------- ----- ----- ----- ----- ----- ------- ------- -----
  Wang et al[@b8-ott-9-1381]     212              168                 47    215   380     592     262   281   123   23    146   404     685     169
  Zhang et al[@b9-ott-9-1381]    148              175                 89    264   323     471     353   265   104   43    147   369     634     190
  Lin et al[@b10-ott-9-1381]     172              136                 50    186   308     480     236   235   90    33    123   325     560     156
  Wang et al[@b11-ott-9-1381]    110              106                 50    156   216     326     206   176   67    23    90    243     419     113
  Hsu et al[@b12-ott-9-1381]     162              96                  40    136   258     420     176   196   77    25    102   273     469     127
  Chang et al[@b13-ott-9-1381]   118              72                  28    100   190     308     128   377   146   57    203   523     900     260
  Wu et al[@b14-ott-9-1381]      151              72                  27    99    223     374     126   330   129   41    170   459     789     211
  Tsou et al[@b15-ott-9-1381]    113              47                  16    63    160     273     79    116   45    15    60    161     277     75
  Liu et al[@b16-ott-9-1381]     704              409                 119   528   1,113   1,817   647   801   311   120   431   1,112   1,913   551
  Bau et al[@b17-ott-9-1381]     238              279                 103   382   517     755     485   397   167   56    223   564     961     279
  Bau et al[@b18-ott-9-1381]     144              160                 71    231   304     448     302   245   96    34    130   341     586     164
  Yang et al[@b19-ott-9-1381]    135              165                 62    227   300     435     289   234   96    32    128   330     564     160

###### 

Meta-analysis of caveolin-1 G14713A polymorphism and cancer susceptibility in Asian population

  Variables                 Allele contrast (A vs G)             Dominant contrast (\[AA + AG\] vs GG)   Recessive contrast (AA vs \[AG + GG\])                                                                                           
  ------------------------- ------------------------------------ --------------------------------------- ---------------------------------------- ------------------- ----- -------- -------- ------------------- ----- -------- -------- -------------------
  All                       86%                                  \<0.01                                  \<0.01                                   1.77 (1.49--2.10)   86%   \<0.01   \<0.01   2.03 (1.64--2.53)   61%   \<0.01   \<0.01   1.72 (1.40--2.12)
  Digestive system cancer   61%                                  0.03                                    \<0.01                                   2.02 (1.75--2.33)   71%   \<0.01   \<0.01   2.40 (1.94--2.98)   0%    0.83     \<0.01   2.01 (1.68--2.40)
  Other cancer types        88%                                  \<0.01                                  \<0.01                                   1.55 (1.18--2.03)   86%   \<0.01   \<0.01   1.72 (1.25--2.36)   70%   0.01     0.02     1.49 (1.06--2.10)
                            **Homozygous contrast (AA vs GG)**   **Heterozygous contrast (AG vs GG)**                                                                                                                                     
  All                       78%                                  \<0.01                                  \<0.01                                   2.24 (1.69--2.98)   79%   \<0.01   \<0.01   1.98 (1.62--2.41)                           
  Digestive system cancer   14%                                  0.32                                    \<0.01                                   2.84 (2.36--3.42)   68%   0.01     \<0.01   2.30 (1.84--2.88)                           
  Other cancer types        81%                                  \<0.01                                  0.01                                     1.81 (1.16--2.84)   78%   \<0.01   \<0.01   1.69 (1.28--2.24)                           

**Abbreviations:** *P*~het~, *P*-value of heterogeneity test; *P*~Z~, *P*-value of *Z*-test; OR, odds ratio; CI, confidence interval.
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